Q-omics provides the consensus-scored NMT2 profile across patient tissues and cancer cell-line models. NMT2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NMT2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, NMT2 RNA expression shows 20,503 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where NMT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NMT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NMT2 survival associations across molecular data types. NMT2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NMT2 RNA expression–survival associations across cancer types. High NMT2 expression shows unfavorable associations in ACC, UCEC, MESO and KIRP, but favorable associations in KIRC and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NMT2 RNA expression.
This table summarizes NMT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NMT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NMT2 shows lower tumor expression in COAD, THCA, KICH, BLCA and BRCA and higher tumor expression in LIHC. The COAD box plot shows higher NMT2 RNA expression in normal versus tumor tissue (log2 FC = −0.931, t-test p < 0.001).
This table shows molecular features associated with NMT2 in patient tissues and cancer cell lines. In patient samples, NMT2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NMT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
